In vitro and in vivo antitumor effects of bisphosphonates

Philippe Clézardin, Pierrick Fournier, Sandrine Boissier, Olivier Peyruchaud

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Bisphosphonates are powerful inhibitors of osteoclast-mediated bone resorption. They are currently used in the palliative treatment of bone metastases. However, bisphosphonates do not only act on osteoclasts. There is now extensive in vitro preclinical evidence that bisphosphonates can act on tumor cells: they inhibit tumor cell adhesion to mineralized bone as well as tumor cell invasion and proliferation. Bisphosphonates induce also tumor cell apoptosis and stimulate γδ T cell cytotoxicity against tumor cells. In vivo, bisphosphonates inhibit bone metastasis formation and reduce skeletal tumor burden. This may reflect direct antitumor effects and indirect effects via inhibition of bone resorption. In addition, bisphosphonates inhibit experimental angiogenesis in vitro and in vivo. Understanding the molecular mechanisms through which bisphosphonates act on tumor and endothelial cells will be undoubtedly an important task in the future. It will allow the design of clinical trials to investigate whether the antitumor activity of bisphosphonates can be realized in the clinical setting.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalCurrent Medicinal Chemistry
Volume10
Issue number2
StatePublished - 2003
Externally publishedYes

Fingerprint

Diphosphonates
Tumors
Bone
Cells
Neoplasms
Osteoclasts
Bone Resorption
Neoplasm Metastasis
Bone and Bones
T-cells
In Vitro Techniques
Cell adhesion
Endothelial cells
Cytotoxicity
Tumor Burden
Palliative Care
Osteogenesis
Cell Adhesion
Endothelial Cells
Cell Proliferation

Keywords

  • Adhesion
  • Angiogenesis
  • Apoptosis
  • Bisphosphonate
  • Bone
  • Invasion
  • Metastasis
  • Proliferation

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Clézardin, P., Fournier, P., Boissier, S., & Peyruchaud, O. (2003). In vitro and in vivo antitumor effects of bisphosphonates. Current Medicinal Chemistry, 10(2), 173-180.

In vitro and in vivo antitumor effects of bisphosphonates. / Clézardin, Philippe; Fournier, Pierrick; Boissier, Sandrine; Peyruchaud, Olivier.

In: Current Medicinal Chemistry, Vol. 10, No. 2, 2003, p. 173-180.

Research output: Contribution to journalArticle

Clézardin, P, Fournier, P, Boissier, S & Peyruchaud, O 2003, 'In vitro and in vivo antitumor effects of bisphosphonates', Current Medicinal Chemistry, vol. 10, no. 2, pp. 173-180.
Clézardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Current Medicinal Chemistry. 2003;10(2):173-180.
Clézardin, Philippe ; Fournier, Pierrick ; Boissier, Sandrine ; Peyruchaud, Olivier. / In vitro and in vivo antitumor effects of bisphosphonates. In: Current Medicinal Chemistry. 2003 ; Vol. 10, No. 2. pp. 173-180.
@article{1234e16f9077494f96fe0ed94a405e70,
title = "In vitro and in vivo antitumor effects of bisphosphonates",
abstract = "Bisphosphonates are powerful inhibitors of osteoclast-mediated bone resorption. They are currently used in the palliative treatment of bone metastases. However, bisphosphonates do not only act on osteoclasts. There is now extensive in vitro preclinical evidence that bisphosphonates can act on tumor cells: they inhibit tumor cell adhesion to mineralized bone as well as tumor cell invasion and proliferation. Bisphosphonates induce also tumor cell apoptosis and stimulate γδ T cell cytotoxicity against tumor cells. In vivo, bisphosphonates inhibit bone metastasis formation and reduce skeletal tumor burden. This may reflect direct antitumor effects and indirect effects via inhibition of bone resorption. In addition, bisphosphonates inhibit experimental angiogenesis in vitro and in vivo. Understanding the molecular mechanisms through which bisphosphonates act on tumor and endothelial cells will be undoubtedly an important task in the future. It will allow the design of clinical trials to investigate whether the antitumor activity of bisphosphonates can be realized in the clinical setting.",
keywords = "Adhesion, Angiogenesis, Apoptosis, Bisphosphonate, Bone, Invasion, Metastasis, Proliferation",
author = "Philippe Cl{\'e}zardin and Pierrick Fournier and Sandrine Boissier and Olivier Peyruchaud",
year = "2003",
language = "English (US)",
volume = "10",
pages = "173--180",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - In vitro and in vivo antitumor effects of bisphosphonates

AU - Clézardin, Philippe

AU - Fournier, Pierrick

AU - Boissier, Sandrine

AU - Peyruchaud, Olivier

PY - 2003

Y1 - 2003

N2 - Bisphosphonates are powerful inhibitors of osteoclast-mediated bone resorption. They are currently used in the palliative treatment of bone metastases. However, bisphosphonates do not only act on osteoclasts. There is now extensive in vitro preclinical evidence that bisphosphonates can act on tumor cells: they inhibit tumor cell adhesion to mineralized bone as well as tumor cell invasion and proliferation. Bisphosphonates induce also tumor cell apoptosis and stimulate γδ T cell cytotoxicity against tumor cells. In vivo, bisphosphonates inhibit bone metastasis formation and reduce skeletal tumor burden. This may reflect direct antitumor effects and indirect effects via inhibition of bone resorption. In addition, bisphosphonates inhibit experimental angiogenesis in vitro and in vivo. Understanding the molecular mechanisms through which bisphosphonates act on tumor and endothelial cells will be undoubtedly an important task in the future. It will allow the design of clinical trials to investigate whether the antitumor activity of bisphosphonates can be realized in the clinical setting.

AB - Bisphosphonates are powerful inhibitors of osteoclast-mediated bone resorption. They are currently used in the palliative treatment of bone metastases. However, bisphosphonates do not only act on osteoclasts. There is now extensive in vitro preclinical evidence that bisphosphonates can act on tumor cells: they inhibit tumor cell adhesion to mineralized bone as well as tumor cell invasion and proliferation. Bisphosphonates induce also tumor cell apoptosis and stimulate γδ T cell cytotoxicity against tumor cells. In vivo, bisphosphonates inhibit bone metastasis formation and reduce skeletal tumor burden. This may reflect direct antitumor effects and indirect effects via inhibition of bone resorption. In addition, bisphosphonates inhibit experimental angiogenesis in vitro and in vivo. Understanding the molecular mechanisms through which bisphosphonates act on tumor and endothelial cells will be undoubtedly an important task in the future. It will allow the design of clinical trials to investigate whether the antitumor activity of bisphosphonates can be realized in the clinical setting.

KW - Adhesion

KW - Angiogenesis

KW - Apoptosis

KW - Bisphosphonate

KW - Bone

KW - Invasion

KW - Metastasis

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=0037241535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037241535&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 173

EP - 180

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 2

ER -